Helios Technologies Declares 98th Sequential Quarterly Cash Dividend
Get Alerts HLIO Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.7%
Revenue Growth %: +0.0%
Join SI Premium – FREE
SARASOTA, Fla.--(BUSINESS WIRE)-- Helios Technologies (Nasdaq: HLIO) (“Helios” or the “Company”) a global leader in highly engineered motion control and electronic controls technology for diverse end markets, announced that its Board of Directors declared a quarterly cash dividend of $0.09 per common share. Helios Technologies has declared ninety-eight consecutive quarterly dividends to its stockholders beginning with the first quarter 1997.
The dividend will be payable on April 20, 2021 to stockholders of record as of April 5, 2021. Helios Technologies has approximately 32.2 million shares of common stock outstanding.
About Helios Technologies
Helios Technologies is a global leader in highly engineered motion control and electronic controls technology for diverse end markets, including construction, material handling, agriculture, energy, recreational vehicles, marine, health and wellness. Helios sells its products to customers in over 85 countries around the world. Its strategy for growth is to be the leading provider in niche markets, with premier products and solutions through innovative product development and acquisition. The company has paid a cash dividend to its shareholders every quarter since becoming a public company in 1997. For more information please visit: www.heliostechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005134/en/
Tania Almond
Vice President, Investor Relations & Corporate Communications
(941) 362-1333
[email protected]
Deborah Pawlowski
Kei Advisors LLC
(716) 843-3908
[email protected]
Source: Helios Technologies
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CVMR Corporation Sets Out its Strategy to Transform Central African Republic's Mineral Resources into High Value Industrial Products
- Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe
- The Next 25 Years of Airport Security
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Dividend, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share